MoonLake Immunotherapeutics (MLTX)
NASDAQ: MLTX · Real-Time Price · USD
17.81
-0.21 (-1.17%)
Mar 6, 2026, 10:41 AM EST - Market open

MLTX Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
41.9730.3222.3223.0121.66
Research & Development
202.86112.7731.842.0512.64
Operating Expenses
244.83143.0954.1265.0634.29
Operating Income
-244.83-143.09-54.12-65.06-34.29
Interest Expense
-7.25----
Currency Exchange Gain (Loss)
0.60.040.150.33-0.07
Other Non Operating Income (Expenses)
21.7722.099.990.27-0
EBT Excluding Unusual Items
-229.71-120.96-43.99-64.47-34.37
Other Unusual Items
-----30
Pretax Income
-229.71-120.96-43.99-64.47-64.37
Income Tax Expense
0.610.280.090.040.01
Earnings From Continuing Operations
-230.32-121.24-44.08-64.51-64.37
Minority Interest in Earnings
32.318.0714.53-
Net Income
-227.32-118.94-36.01-49.97-64.37
Net Income to Common
-227.32-118.94-36.01-49.97-64.37
Shares Outstanding (Basic)
646349298
Shares Outstanding (Diluted)
646349298
Shares Change (YoY)
2.54%27.99%67.30%274.47%-
EPS (Basic)
-3.53-1.89-0.73-1.70-8.21
EPS (Diluted)
-3.53-1.89-0.73-1.70-8.21
Free Cash Flow
-196.04-117.11-43.06-55.91-42.27
Free Cash Flow Per Share
-3.04-1.86-0.88-1.90-5.39
EBITDA
-242.22-141.71-53.75-64.9-34.29
D&A For EBITDA
2.621.390.370.160.01
EBIT
-244.83-143.09-54.12-65.06-34.29
Source: S&P Capital IQ. Standard template. Financial Sources.